Sun Pharma jumps 2% as partner gets drug nod
The stock rose 2.28 per cent to hit a high of Rs 657 on the BSE.
By ETMarkets.com |
BCCL
NEW DELHI: Shares of Sun Pharma advanced 2 per cent on Wednesday as its partner Almirall received approval from European drug regulators for its psoriasis drug Tildrakizumab.
The drug is used for treatment of adults with moderate-to-severe chronic plaque psoriasis, a chronic immunity disease that affects skin.
The stock rose 2.28 per cent to hit a high of Rs 657 on the BSE.
In July 2016, Sun Pharma out-licensed tildrakizumab to Almirall for development and mercialisation of the product in Europe. The rollout in Europe will start in the next few weeks, the company said in a BSE filing.
The drug is used for treatment of adults with moderate-to-severe chronic plaque psoriasis, a chronic immunity disease that affects skin.
The stock rose 2.28 per cent to hit a high of Rs 657 on the BSE.
In July 2016, Sun Pharma out-licensed tildrakizumab to Almirall for development and mercialisation of the product in Europe. The rollout in Europe will start in the next few weeks, the company said in a BSE filing.
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
ADVERTISEMENT
